Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Patient Access Advocacy for BTK Inhibitors

The Inflation Reduction Act: Implications for Patient Access in CL

Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Decision-Making in CLL: The Role of Real-World Evidence

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Optimizing Therapy Sequencing in CLL

Empowering Patients: Key Considerations for BTK Inhibitor Adherence

New Findings Highlight Key Role of Clinician Communication in Lymphoma, CLL Care: Lorna Warwick

Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

Navigating Value, Efficacy in Modern CLL Treatment: Pierluigi Porcu, MD

Advancing Hematologic Care and the Future of Shared Decision-Making

Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients

Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences

Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making

Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi